DE3485649D1 - Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. - Google Patents

Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.

Info

Publication number
DE3485649D1
DE3485649D1 DE8484306027T DE3485649T DE3485649D1 DE 3485649 D1 DE3485649 D1 DE 3485649D1 DE 8484306027 T DE8484306027 T DE 8484306027T DE 3485649 T DE3485649 T DE 3485649T DE 3485649 D1 DE3485649 D1 DE 3485649D1
Authority
DE
Germany
Prior art keywords
serum half
value
therapeutic agents
antibody compositions
producing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8484306027T
Other languages
English (en)
Inventor
James M Frincke
Barbara W Unger
Karen G Burnett
Evan Myron Hersh
Michael Gordon Rosenblum
Jordan Udell Gutterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Application granted granted Critical
Publication of DE3485649D1 publication Critical patent/DE3485649D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8484306027T 1983-09-01 1984-09-03 Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. Expired - Fee Related DE3485649D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08323428A GB2148299B (en) 1983-09-01 1983-09-01 Antibody compositions of therapeutic agents having an extended serum half-life

Publications (1)

Publication Number Publication Date
DE3485649D1 true DE3485649D1 (de) 1992-05-21

Family

ID=10548161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484306027T Expired - Fee Related DE3485649D1 (de) 1983-09-01 1984-09-03 Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.

Country Status (11)

Country Link
US (1) US5055289A (de)
EP (1) EP0136835B1 (de)
JP (1) JPH0717519B2 (de)
AT (1) ATE74766T1 (de)
AU (1) AU593208B2 (de)
CA (1) CA1249222A (de)
DE (1) DE3485649D1 (de)
DK (1) DK191985D0 (de)
FI (1) FI85441C (de)
GB (1) GB2148299B (de)
WO (1) WO1985000974A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
ATE106250T1 (de) * 1987-07-07 1994-06-15 Hybrisens Ltd Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.
JPH03503840A (ja) * 1988-01-15 1991-08-29 セントコアー，インコーポレーテッド 異種連結抗体およびその治療的使用
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5225540A (en) * 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
ATE113846T1 (de) * 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE106251T1 (de) * 1990-02-06 1994-06-15 Takeda Chemical Industries Ltd Immunkomplexe.
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
JP2001502895A (ja) * 1996-09-20 2001-03-06 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
AU9676598A (en) * 1997-09-30 1999-04-23 Duke University Apolipoprotein e/growth factor complexes and methods of use
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003059251A2 (en) * 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
AU2002337954C1 (en) * 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
EP1426382A1 (de) * 2002-12-06 2004-06-09 Aventis Behring GmbH Antivirales menschliches Serum Albumin
EP1731168A1 (de) * 2004-03-30 2006-12-13 Takeda Pharmaceutical Company Limited Antikörper-arzneimittel
KR20070083809A (ko) * 2004-10-07 2007-08-24 유니베르시태트 취리히 건선 예방 및 치료용 ⅰ형 인터페론 차단제
EP1863847A2 (de) * 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 antikörper und deren therapeutische verwendung
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
BRPI0619224A2 (pt) * 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
BRPI0912570B8 (pt) 2008-05-07 2021-05-25 Argos Therapeutics Inc anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
KR102094022B1 (ko) 2013-04-29 2020-03-30 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
BR112017008880A2 (pt) 2014-10-29 2018-07-10 Teva Pharmaceuticals Australia Pty Ltd variantes de interferon a2b
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509707A (en) * 1974-09-20 1978-05-04 Searle & Co Immunological compounds
US4195017A (en) * 1975-02-25 1980-03-25 Samuel Bogoch Malignin, derived from brain tumor cells, complexes and polypeptides thereof
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616417A (en) * 1979-07-19 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
EP0044167A3 (de) * 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2098219A (en) * 1981-05-08 1982-11-17 Erba Farmitalia Daunorubicin-protein conjugates
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
DK173435B1 (da) * 1983-08-17 2000-10-23 Wellcome Found Injicerbare præparater samt fremgangsmåder til potentiering af administrering af et hormon til normale hvirveldyr eller til

Also Published As

Publication number Publication date
FI851635A0 (fi) 1985-04-25
GB2148299B (en) 1988-01-06
ATE74766T1 (de) 1992-05-15
FI85441C (fi) 1992-04-27
AU3393584A (en) 1985-03-29
WO1985000974A1 (en) 1985-03-14
FI851635L (fi) 1985-04-25
DK191985A (da) 1985-04-29
GB8323428D0 (en) 1983-10-05
US5055289A (en) 1991-10-08
GB2148299A (en) 1985-05-30
FI85441B (fi) 1992-01-15
EP0136835B1 (de) 1992-04-15
DK191985D0 (da) 1985-04-29
EP0136835A3 (en) 1986-10-08
JPS60502104A (ja) 1985-12-05
EP0136835A2 (de) 1985-04-10
JPH0717519B2 (ja) 1995-03-01
AU593208B2 (en) 1990-02-08
CA1249222A (en) 1989-01-24

Similar Documents

Publication Publication Date Title
DE3485649D1 (de) Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.
ATE160583T1 (de) Steigerungsverfahren der transmembranförderung von exogenen molekülen
DD128170A5 (de) Verfahren zur herstellung von praeparaten mit geregelter wirkstoffabgabe
MX7235E (es) Procedimiento para preparar una solucion inyectable intravenosamente de globulina de suero inmune
ATE123227T1 (de) Kationisierte antikörper für das austragen durch die blut-gehirn-schranke.
DD129788A5 (de) Verfahren zur herstellung von 3',3'',5',5''-tetrachlorphenol-3,4,5,6-tetrabromsulfophthalein bzw.3',3''-dibrom-5',5''-dichlorphenol-3,4,5,6-tetrachlorsulfophthalein
ATE866T1 (de) Immunserumglobulin (isg)-praeparate und verfahren zu ihrer herstellung.
ATE98631T1 (de) Verfahren zur herstellung von komplexverbindungen.
AT339267B (de) Verfahren zur selektiven herstellung von alkyl-tert.butylathern
ATE57694T1 (de) Verfahren zur herstellung von 2,5dicetopiperazinen.
ATA395576A (de) Verfahren zur herstellung von nicht mehr antikomplementaer wirksamen nativ-human- -immunglobulin zur intravenoesen verabreichung mit natuerlicher halbwertszeit
SE7609055L (sv) Veterinerkompositioner
JPS5547627A (en) Manufacture of immune globulin solution good for intravenous application
AT359197B (de) Verfahren zur herstellung von pharmazeutischen praeparaten
DK398483D0 (da) Substiuerede tert.butanolderivater, fremgangsmader til fremstilling deraf samt antimykotiske midler indeholdende disse forbindelser
ATE124268T1 (de) Verfahren zur herstellung von therapeutischen rhenium-phosphonat-mitteln.
AT344885B (de) Verfahren zur herstellung von 18-arabinosyl-2-n-butyl-3,7,11,15,19,21,23,25,27,37-dekahydroxy-4,16,32,34,36-pentamethyl-tetrakonta-16,32-dien-35-o-lacton-40-guanidiniumsulfat(debrycin) enthaltenden pharmazeutischen praeparaten
JPS5235277A (en) Process for producing fiberrreinforced hoseeshaped object composed of chemically denatured protein plastic
ES8601694A1 (es) Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrina
NL7603461A (nl) D-homosteroiden en werkwijze voor de bereiding daarvan.
AT238704B (de) Verfahren zur Herstellung von dimerem Bis-(cyclopentadienyl)-buten-(2)
ES381207A1 (es) Un procedimiento para preparar nuevas 1,2-difenil-3,5-dioxo-pirazolidinas sustituidas en la posicion 4.
GB1136039A (en) Improvements relating to immunosuppressive agents
DE69426149D1 (de) Ecdysone zur verbesserung der produktivität von wiederkäuern
ES8505513A1 (es) Procedimiento para la fabricacion de aminoacetonitrilos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee